Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,202 across all filing types
Latest filing 2022-05-20 AGM Information
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
2021年年度股东大会法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2021 Annual General Meeting (AGM) of Lingkang Pharmaceutical Group Co., Ltd. It discusses the legality of the AGM's convening, the qualifications of attendees, the voting procedures, and the voting results. The document does not contain the actual annual report or financial statements but rather provides a legal opinion on the AGM process and outcomes. The document length is 3524 characters, which is relatively short and focused on the AGM event. Therefore, it fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the AGM, including legal opinions related to the AGM.
2022-05-20 Chinese
2021年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a 2021 Annual General Meeting (AGM) resolution announcement for Lingkang Pharmaceutical Group Co., Ltd. It details the date and location of the AGM, attendance, voting results on various proposals including the 2021 annual report, financial statements, profit distribution plan, and credit facility approvals. It also includes legal opinions confirming the legality of the meeting and voting procedures. The document is an official announcement of the AGM resolutions and voting outcomes rather than the full annual report or financial statements themselves. The document length is 3257 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-05-20 Chinese
关于控股股东股票质押式回购交易延期购回及补充质押的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the extension of the repurchase period and supplementary pledge of shares by the controlling shareholder of the company. It details the number of shares pledged, the pledge period extension, and the impact on the company. There is no financial statement or report content, but rather a disclosure about share pledge transactions by a major shareholder. This fits the category of a Capital/Financing Update, as it relates to financing activities involving share pledges and repurchase transactions. The document length is short and focused on this specific financing event, not a full financial report or regulatory filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2022-05-20 Chinese
2021年年度股东大会会议材料
AGM Information Classification · 100% confidence The document is titled as the 2021 Annual General Meeting (AGM) materials for Lingkang Pharmaceutical Group Co., Ltd. It includes detailed agenda items such as the 2021 Board of Directors work report, Supervisory Board work report, full annual report and summary, financial settlement report, profit distribution plan, and other proposals. The document also contains meeting procedures, voting methods, and legal opinions related to the AGM. The content is consistent with materials prepared and distributed for an Annual General Meeting, rather than the annual report itself or voting results. The document length is substantial (15,000 characters), indicating it is the full meeting materials, not just an announcement or a brief summary. Therefore, the appropriate classification is AGM Information (AGM-R).
2022-05-13 Chinese
中信证券股份有限公司关于灵康药业集团股份有限公司2020年公开发行可转换公司债券保荐总结报告书
Capital/Financing Update Classification · 95% confidence The document is a detailed report titled '保荐总结报告书' (Sponsorship Summary Report) related to the 2020 public issuance of convertible bonds by Lingkang Pharmaceutical Group Co., Ltd. It includes comprehensive information about the issuer, the bond issuance, regulatory approvals, the sponsor's ongoing supervision work, investigation of related party fund occupation, corrective measures, and conclusions on information disclosure and fund usage. The document is about 4197 characters long, which is substantial and contains detailed substantive content rather than just an announcement or certification. It is not an annual report, earnings release, or a call transcript. It is a specialized report related to the sponsorship and supervision of a capital market issuance, which fits best under the category of Capital/Financing Update (CAP).
2022-05-10 Chinese
中信证券股份有限公司关于灵康药业集团股份有限公司持续督导现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "持续督导现场检查报告" (Continuous Supervision On-site Inspection Report) issued by the sponsor institution 中信证券股份有限公司 regarding 灵康药业集团股份有限公司. It details the sponsor's on-site inspection of the company's compliance with regulatory requirements, focusing on issues such as related party non-operating fund occupation, internal control deficiencies, governance, information disclosure, and fundraising usage. The report includes detailed findings, corrective measures, and recommendations. It is a standalone audit/inspection report related to regulatory compliance and internal controls, not a full annual or interim financial report, nor an announcement or presentation. The document length (5058 characters) and content indicate it is a substantive report rather than a brief announcement or certification. Therefore, the most appropriate classification is Audit Report / Information (AR). FY 2021
2022-05-10 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.